Ideaya Biosciences (IDYA) said Thursday it launched a phase 1/2 expansion in a clinical trial of its experimental IDE397 treatment in combination with Gilead Sciences' (GILD) Trodelvy in methylthioadenosine phosphorylase, or MTAP-deletion urothelial cancer, based on preliminary safety and clinical efficacy data.
The prevalence of MTAP-deletion is estimated at 26% in the cancer type, the company said. An update on the program is planned later this year.
Ideaya said it is the study sponsor, while Gilead will supply Trodelvy.
Ideaya shares were up 4.4% in recent premarket activity, while Gilead rose 1.4%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。